US › Healthcare

Kiora Pharmaceuticals Inc (KPRX)

US · Healthcare · Biotechnology

$2.40-0.41%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-2.1M

EPS

$-0.34

EPS estimate

$-0.62

EPS came in at -0.34 against a street estimate of -0.62 — a beat of 45.2%.

Key statistics

Market cap

$10.9M

Forward P/E

2.4

P/B

0.69

Book value

$2.65

EPS (TTM)

$-2.46

52-week high

$2.91

52-week low

$1.76

50-day MA

$2.59

200-day MA

$2.40

Beta

-0.21

Analyst view

Analysts rate Kiora Pharmaceuticals Inc a buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $12.00.

Shareholding

Insiders

8.91%

Institutions

36.35%

Largest institutional holders

Fund	Stake
Perceptive Advisors LLC	9.91%
ADAR1 Capital Management LLC	3.80%
Citadel Advisors Llc	2.62%
Two Sigma Investments LLC	2.01%
Millennium Management LLC	1.68%
HRT FINANCIAL LLC	1.32%
Renaissance Technologies Corp	0.67%
Geode Capital Management, LLC	0.60%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Kiora Pharmaceuticals Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-18.